Patients with HF face an Ongoing Burden, and Prevalence is on the Rise1,2

Half of all HF cases in the US are characterized by HFrEF, and the majority of patients remain symptomatic, even with treatment.2‑4

Despite advances in treatment, hospitalizations and rehospitalizations for patients with HF remain high2,3,5,6

The risk of death increases with each additional hospitalization7,8

• 50% of patients in a study died within a year of their 3rd hospitalization8,†

Hear about a patient’s experience with HF

*Based on data from NHANES 2013‑2016.3
†In a study of 14,374 patients hospitalized for HF from 2000–2004.8
‡In an investigational study of patients with an index hospitalization for HF from California, New York, and Florida from 2007–2011 (N=547,068).6
§Among patients with HFrEF (n=18,398) in the GWTG‑HF registry, a study of patients on Medicare and Medicaid services (N=39,982).9

 

GWTG‑HF, Get With The Guidelines®‑Heart Failure; HF, heart failure; HFrEF, heart failure with reduced ejection fraction.

 

References:
1. Sidney S, et al. JAMA Cardiol. 2019;4:1280‑1286. 2. Reddy YNV, et al. Eur Heart J. 2020;41:1764‑1774. 3. Benjamin EJ, et al. Circulation. 2019;139:e56‑e528. 4. Basuray A, et al. Circulation. 2014;129:2380‑2387. 5. Adams KF Jr, et al. Am Heart J. 2005;149:209‑216. 6. Davis JD, et al. Am J Med. 2017;130:93.e9‑93.e28. doi:10.1016/j.amjmed.2016.07.030. 7. Greene SJ, et al. Nat Rev Cardiol. 2015;12:220‑229. 8. Setoguchi S, et al. Am Heart J. 2007;154:260‑266. 9. Shah KS, et al. J Am Coll Cardiol. 2017;70:2476‑2486.